22 results
Search Results
2. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases.
- Author
-
Gehl, Julie, Sersa, Gregor, Matthiessen, Louise Wichman, Muir, Tobian, Soden, Declan, Occhini, Antonio, Quaglino, Pietro, Curatolo, Pietro, Campana, Luca G., Kunte, Christian, Clover, A. James P., Bertino, Giulia, Farricha, Victor, Odili, Joy, Dahlstrom, Karin, Benazzo, Marco, and Mir, Lluis M.
- Subjects
CANCER treatment ,METASTASIS ,ANTINEOPLASTIC agents ,CANCER chemotherapy ,CELL membranes ,DECISION making ,ELECTROTHERAPEUTICS ,SKIN tumors ,OPERATIVE surgery ,TREATMENT effectiveness ,TUMOR treatment - Abstract
Electrochemotherapy is now in routine clinical use to treat cutaneous metastases of any histology, and is listed in national and international guidelines for cutaneous metastases and primary skin cancer. Electrochemotherapy is used by dermatologists, surgeons, and oncologists, and for different degrees and manifestations of metastases to skin and primary skin tumours not amenable to surgery. This treatment utilises electric pulses to permeabilize cell membranes in tumours, thus allowing a dramatic increase of the cytotoxicity of anti-cancer agents. Response rates, often after only one treatment, are very high across all tumour types. The most frequent indications are cutaneous metastases from malignant melanoma and breast cancer. In 2006, standard operating procedures (SOPs) were written for this novel technology, greatly facilitating introduction and dissemination of the therapy. Since then considerable experience has been obtained treating a wider range of tumour histologies and increasing size of tumours which was not originally thought possible. A pan-European expert panel drawn from a range of disciplines from dermatology, general surgery, head and neck surgery, plastic surgery, and oncology met to form a consensus opinion to update the SOPs based on the experience obtained. This paper contains these updated recommendations for indications for electrochemotherapy, pretreatment information and evaluation, treatment choices, as well as follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Post-transplant Merkel Cell Carcinoma.
- Author
-
KOLJONEN, Virve, SAHI, Helka, BÖHLING2, Tom, and MÄKISALO3, Heikki
- Subjects
MERKEL cell carcinoma ,DRUG side effects ,IMMUNOSUPPRESSIVE agents ,TRANSPLANTATION of organs, tissues, etc. ,CANCER treatment ,SKIN cancer ,THERAPEUTICS - Abstract
Malignant tumours are the foremost complications of immunosuppressive treatment. They are a major challenge for organ transplant recipients and their treating physicians. This paper reviews the aetiology and current treatment of an unusual neuroendocrine skin cancer, Merkel cell carcinoma (MCC), caused by a Merkel cell polyomavirus infection. MCC occurs more frequently than expected in immunosuppressed subjects, especially in organ transplant recipients. The current literature comprises reports of 79 organ transplant recipients with MCC. The risk of MCC in organ transplant recipients is increased up to 66-182-fold compared with the general population. In addition to the increased risk of developing MCC, immunosuppressed individuals have poorer MCC-specific survival. The aim of this review article is to familiarize organ transplant doctors with this unique and clinically challenging skin cancer, and to provide recent data on the diagnosis and current treatment recommendations for an immunosuppressed population. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. The effect of a smoking cessation program for patients in cancer treatment: a quasi-experimental intervention study.
- Author
-
Kvaavik, Elisabeth, Weemes Grøtting, Maja, Halkjelsvik, Torleif, van Helvoirt, Rene, Kirkhorn, Ingeborg Hjertvik, Bjaanes, Maria Moksnes, Tøndel, Hanne, Sværen, Julia Thue, Gripsgård, Helga, Byrkje, Kristin, and Helleve, Arnfinn
- Subjects
TUMOR treatment ,EVALUATION of human services programs ,SMOKING cessation ,CONFIDENCE intervals ,HUMAN research subjects ,CLINICAL trials ,MOTIVATIONAL interviewing ,RESEARCH methodology ,SELF-evaluation ,AGE distribution ,CANCER patients ,PRE-tests & post-tests ,SEX distribution ,DESCRIPTIVE statistics ,RESEARCH funding ,CONTROL groups ,SMOKING ,LABOR market ,SMOKING cessation products ,EDUCATIONAL attainment - Abstract
Compared to non-smokers, smokers have reduced effects of cancer treatment, and increased risk of treatment-related toxicity. Quitting smoking can improve treatment effects and reduce side effects. This study reports on the potential impact of a smoking cessation program on smoking cessation rates among patients in cancer treatment. Cancer patients 18 years and older who smoked, with survival prognosis ≥12 months, not suffering dementia or other mental illness, and who were referred to cancer treatment at six Norwegian hospitals were invited to participate. The study took place from 2017 to 2020 and used a pre-test-posttest non-equivalent control group design. The intervention group received structured smoking cessation guidance based on Motivational Interviewing combined with cost-free nicotine replacement products, while the control group received standard smoking cessation treatment. Self-reported smoking status were registered at baseline and at 6 months' follow up. 76% of patients smoked at baseline and 44% at follow-up in the intervention group, correspondingly 72% and 49% in the control group. In an analysis of differences in within-person change, the reduction in the intervention group was 13 percentage points larger (95% CI = (0.25, −0.005), p = 0.041). Adjusting for gender, age, education, labour market participation and partnership status did not attenuate the estimated effect (18 percentage point difference, 95% CI = (−0.346, −0.016), p = 0.032). Demographic factors and dropout rate differed somewhat between the groups with a higher dropout rate in the intervention group, 54% vs. 51%, respectively). Offering a structured smoking cessation program based on Motivational Interviewing and cost-free nicotine replacement products to cancer patients can increase cessation rates in comparison to standard smoking cessation care. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Response to the Letter by Leitch et al.
- Author
-
Paoli, John, Börve, Alexander, Gyllencreutz, Johan Dahlén, Terstappen, Karin, Backman, Eva Johansson, Aldenbratt, Anette, Danielsson, Markus, Gillstedt, Martin, and Sandberg, Carin
- Subjects
MEDICAL referrals ,SKIN cancer ,CANCER treatment ,TELEMEDICINE - Abstract
A response from the author of the article "Smartphone teledermoscopy referrals: a novel process for improved triage of skin cancer patients" in the 2015 issue is presented.
- Published
- 2015
6. Evaluating comprehensive cancer networks; a review of standards and evaluation methods for care networks to inform a comparison with the OECI comprehensive cancer network standards.
- Author
-
Wind, Anke, Oberst, Simon, Westerhuis, Willien, Blaauwgeers, Harriet, Sæter, Gunnar, de Paoli, Paolo, Nagy, Péter, Burrion, Jean-Benoit, Jolly, Eva, Lovey, József, and van Harten, Wim
- Subjects
MEDICAL quality control ,EVALUATION of medical care ,SPECIALTY hospitals ,KEY performance indicators (Management) ,SYSTEMATIC reviews ,CANCER treatment ,QUALITY assurance ,CLINICAL medicine ,RESEARCH funding ,LITERATURE reviews ,CANCER patient medical care - Abstract
To ensure that all citizens have equal access to high-quality cancer diagnosis and care, the EU4Health Programme, Europe's Beating Cancer Plan, and Horizon Europe's Cancer Mission propose Comprehensive Cancer Infrastructures in every European Union Member State. It is therefore important to establish the basic principles for high-performing cancer networks and a methodology for evaluating their quality and effectiveness. This article describes methods and standards/indicators for network evaluation found in literature, gives a comparative overview of the new OECI European Cancer Network Quality standards, and proposes principles for evaluating the performance of Comprehensive Cancer Networks as a basis for continuous improvement. We performed a scoping literature review on methods and standards/indicators for care-network evaluation. We then compared the OECI set with literature findings, categorised standards that were similar, reflected on standards that were different, and deduced principles for quality standards for cancer networks. Of 1002 articles identified, 17 reported on evaluation methods and/or (mostly) qualitative indicators. Sixteen studies described indicators/standards for evaluating care networks, critical success factors or desirable outcomes. Of the 54 present OECI standards, 32 had a literature equivalent. No literature equivalent was found for 22 standards, especially on those related to the combination of care and research. The proposed OECI evaluation methods (survey, document review, and interviews) were all reported in the literature. From the conformity of these results, we deduced 8 principles for standards evaluating the effectiveness of Comprehensive Cancer Networks. Research on the evaluation of the effectiveness of care networks is scarce. Evaluation methods vary and are often single time-point assessments. The OECI set contributes to establishing clear principles and standards to evaluate the effectiveness of Comprehensive Cancer Networks. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. The prevalence, distribution and impact of peripheral neuropathy among Danish patients with cancer – a population-based cross-sectional study.
- Author
-
Nielsen, Sebastian Werngreen, Eckhoff, Lise, Ruhlmann, Christina Halgaard Bruvik, Herrstedt, Jørn, and Dalton, Susanne Oksbjerg
- Subjects
PERIPHERAL neuropathy diagnosis ,PERIPHERAL neuropathy ,CANNABIS (Genus) ,SUBSTANCE abuse ,CONFIDENCE intervals ,CANCER chemotherapy ,CROSS-sectional method ,AGE distribution ,POLYPHARMACY ,ANTINEOPLASTIC agents ,DIABETES ,CANCER patients ,SEX distribution ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,OBSTRUCTIVE lung diseases ,QUALITY of life ,TUMORS ,SMOKING ,ARTHRITIS ,HEART diseases - Abstract
Prevalence of peripheral neuropathy (PN) has been studied in patients undergoing treatment with taxanes, platinums and vinca alkaloids. The prevalence is unknown in the general oncological cancer population, characterized by advanced age, comorbidities and heterogeneous treatments. A cross-sectional survey was administered to all adult patients, attending outpatient services at three Danish departments of oncology. The survey contained the EORTC-CIPN20, the EORTC-QLQ-C30, the GAD7 and PHQ9 questionnaires. A high PN symptom score was defined as a summary score ≥30 points on the CIPN20. P-values were adjusted for multiple testing. With an overall response rate of 83% (2839 patients), prevalence of PN was 17% overall, varying from 6 to 33% between diagnosis groups. A high score was more common among females (19 vs. 14%, p =.008), smokers (21 vs. 15%, p =.04), patients living alone (21 vs. 15%, p =.002) and patients using cannabis (29 vs. 15%, p <.001), as well as patients suffering from diabetes (26 vs. 16%, p <.001), cardiac heart disease (27 vs. 16%, p <.001), arthritis (32 vs. 15%, p <.001) or chronic obstructive pulmonary disease (25 vs. 16%, p =.01). High score patients were also older (69ys vs 67ys, p =.048) and more likely experiencing polypharmacy (OR = 3.38 [95% CI, 2.64;4.35]). Patients with a high CIPN20 symptom score scored worse on all EORTC QLQ-C30 function and symptom scales. The mean adjusted C30 SumScore difference was −18.66 ([95% CI, −20.31; −17.02], p <.001). Symptoms of PN are experienced widely across cancer groups in the oncology setting. PN symptoms were associated with clinically relevant worse health-related quality of life and with patient-related factors as living alone, various comorbidities, polypharmacy, and cannabis use. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Is there a Nordic solution for the 'proton-problem'?
- Author
-
Bergfeldt, Kjell, Nystrom, Håkan, Witt Nystrom, Petra, and Høyer, Morten
- Subjects
TUMOR treatment ,CANCER patients ,CANCER treatment ,HEALTH facilities ,MEDICAL care costs ,RADIOTHERAPY ,SERIAL publications ,ADULT education workshops ,SPECIALTY hospitals ,PROTON therapy - Abstract
An introduction is presented in which the editor discusses several articles published within issue on topics including proton therapy indications and strategies for identification of patients for proton therapy, property of proton therapy, and patient's perspective in proton therapy.
- Published
- 2020
- Full Text
- View/download PDF
9. 50 Years of the IAEA/WHO postal dose audit programme for radiotherapy: what can we learn from 13756 results?
- Author
-
Izewska, Joanna, Bokulic, Tomislav, Kazantsev, Pavel, Wesolowska, Paulina, and van der Merwe, Debbie
- Subjects
RADIATION therapy equipment ,AUDITING ,CANCER treatment ,CLINICAL competence ,COBALT ,COMMUNITY health services ,COMPARATIVE studies ,HEALTH services administration ,INTERNATIONAL agencies ,MEDICAL protocols ,NUCLEAR energy ,POSTAL service ,QUALITY assurance ,RADIATION doses ,RADIATION dosimetry ,TIME ,ORGANIZATIONAL structure ,SPECIALTY hospitals ,EVALUATION of human services programs ,DESCRIPTIVE statistics ,MIDDLE-income countries ,LOW-income countries - Abstract
Background: The IAEA/WHO postal dose audit programme has been operating since 1969 with the aim of improving the accuracy and consistency of dosimetry in radiotherapy in low-income and middle-income countries world-wide. This study summarises the 50 years' experience of audits and explores the quality of reference dosimetry in participating radiotherapy centres throughout the years. Material and methods: During the IAEA/WHO postal audits the dose determined from the mailed dosimeter is compared with that stated by the participant. Agreement to within ±5% is regarded acceptable whilst deviations outside ±5% limits trigger follow-up actions. Of particular interest in this study was the dependence of clinical dosimetry quality on factors related to the centre infrastructure and expertise in dosimetry of its staff. Results: The IAEA/WHO dose audit programme noted great increase in the overall percentage of acceptable results from about 50% in its early years to 99% at present, although there is some variability of results amongst participating countries. Whereas results for younger radiotherapy machines show the agreement rate between the measured and the stated doses well above 90%, for those over 20 years old the rate dropped to <80%. Linac dosimetry was always better than
60 Co dosimetry and multi-machine centres generally performed better than single machine centres equipped with cobalt alone. Second and subsequent participation in audits showed higher quality dosimetry than the first participation. The implementation of modern dosimetry protocols resulted in more accurate dosimetry than the use of the older protocols. Conclusions: Over the 50 years that the IAEA has accumulated dosimetry audit data, practices in radiotherapy centres have significantly improved. Higher quality dosimetry confirmed in audits is generally associated with better infrastructure and adequate dosimetry expertise of medical physicists in participating centres. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
10. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
- Author
-
Zimmermann, Michel, Beer, Jürgen, Bodis, Stefan, von Moos, Roger, Vlachopoulou, Vasiliki, Zwahlen, Daniel R., and Oehler, Christoph
- Subjects
FLUOROURACIL ,CANCER treatment ,SQUAMOUS cell carcinoma ,ANAL tumors ,COMBINED modality therapy ,DIARRHEA ,GASTROINTESTINAL diseases ,LONGITUDINAL method ,MAGNETIC resonance imaging ,NEUTROPENIA ,RADIOTHERAPY ,SKIN inflammation ,SURVIVAL analysis (Biometry) ,POSITRON emission tomography ,TUMOR classification ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,TUMOR treatment - Abstract
Background:To evaluate local control (LC), survival and toxicity in anal cancer patients treated with intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy at a single institution. Material and methods:From August 2010 to May 2015, 26 patients were treated at our institution with IMRT and concurrent 5-fluorouracil/mitomycin-C (5-FU/MMC) for localized squamous cell carcinoma of the anal canal (SCCAC). Radiotherapy (RT) with 50.4–60 Gy was delivered with a sequential boost in 31%, and a simultaneous-integrated boost (SIB-IMRT) in 69% of cases. Initial staging was based on PET-CT and MRI. Clinical measures of interest were the influence of PET-CT on staging and treatment planning, LC, disease free survival (DFS), overall survival (OS), colostomy free survival (CFS) and toxicities. Results:Median age was 61 years, 22 patients (85%) were female, and no patient was HIV-positive. The proportion of patients with stage I, II, IIIA and IIIB disease was 15%, 35%, 23% and 27%, respectively. PET-CT modified the extent of nodal disease in 9/23 cases (39%) and lead to major changes in treatment planning in 4/23 patients (17%). MRI was more accurate at identifying T4 disease. RT was delivered at full dose in 26 patients (100%) and chemotherapy in 22/26 patients (85%). Two patients (7.7%) required RT breaks. Median follow-up was 35 months [IQR: 19–52]. The 2-year LC, DFS, OS and CFS were 100%, 100%, 100% and 92%. Acute grade ≥3 dermatitis and diarrhea occurred in 73% and 8% of cases, respectively. Grade 3–4 neutropenia was seen in 10/23 patients (43%). Four patients (15%) developed chronic grade 2 GI toxicity. Conclusions:PET-CT provided additional information leading to major changes in treatment planning for 17% of patients. Considering our excellent outcomes, routine use of PET-CT as standard staging modality and IMRT planning procedure appears justified for patients with SCCAC. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
11. Impact of High Age and Comorbidity on Management Decisions and Adherence to Guidelines in Patients with Keratinocyte Skin Cancer.
- Author
-
LUBEEK, Satish F. K., MICHIELSENS, Celia A. J., BORGONJEN, Rinke J., BRONKHORST, Ewald M., VAN DE KERKHOF, Peter C. M., and GERRITSEN, Marie-Jeanne P.
- Subjects
PATIENT compliance ,KERATINOCYTES ,SKIN cancer patients ,CANCER treatment ,SKIN cancer ,LIFE expectancy ,GERIATRIC dermatology - Abstract
Appropriate medical decision-making in patients with keratinocyte skin cancer (KSC) can be challenging, especially in those with a limited life expectancy (LEx). Treatment should be beneficial for the individual patient, the risk of both over- and under-treatment should be carefully considered, and deviation from guideline recommendations may be necessary. In this study retrospective analysis was performed to determine the influence of age and comorbidity, both factors strongly related to limited LEx, on KSC management in daily practice. After analysis of 401 patients it was found that management in patients with KSC is not influenced, or is only minimally influenced, by high age and comorbidity. Better integration of aspects related to a limited LEx in KSC management might optimize care and prevent overtreatment. Future research on the general prognostication, prediction of the patient burden caused by tumour and treatment, and time-to-benefit in KSC management is strongly recommended. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
12. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
- Author
-
Mellon, Eric A., Jin, William H., Frakes, Jessica M., Centeno, Barbara A., Strom, Tobin J., Springett, Gregory M., Malafa, Mokenge P., Shridhar, Ravi, Hodul, Pamela J., and Hoffe, Sarah E.
- Subjects
ADENOCARCINOMA ,CANCER treatment ,DOCETAXEL ,THERAPEUTIC use of antimetabolites ,CANCER chemotherapy ,COMBINED modality therapy ,COMPUTED tomography ,DEOXY sugars ,ENDOSCOPY ,PANCREATIC tumors ,PANCREATECTOMY ,RADIOPHARMACEUTICALS ,RADIOSURGERY ,POSITRON emission tomography ,TUMOR markers ,LOGISTIC regression analysis ,TREATMENT effectiveness ,DISEASE progression ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,LOG-rank test - Abstract
Background:Neoadjuvant therapy response correlates with survival in multiple gastrointestinal malignancies. To potentially augment neoadjuvant response for pancreas adenocarcinoma, we intensified treatment with stereotactic body radiotherapy (SBRT) following multi-agent chemotherapy. Using this regimen, we analyzed whether the College of American Pathology (CAP) tumor regression grade (TRG) at pancreatectomy correlated with established response biomarkers and survival. Materials and methods:We identified borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer patients treated according to our institutional clinical pathway who underwent surgical resection with reported TRG (n = 81, median follow-up after surgery 24.2 months). Patients had baseline CA19-9, computed tomography (CT), endoscopic ultrasound, and FDG positron emission tomography (PET)/CT then underwent multi-agent chemotherapy (79% with three cycles of gemcitabine, docetaxel and capecitabine) followed by 5-fraction SBRT. They then underwent restaging CT, PET/CT and CA19-9. Overall (OS) and progression-free (PFS) survival were estimated and compared by Kaplan–Meier and log-rank methods. Univariate ordinal logistic regression correlated TRG with baseline, restaging and change in CA19-9 and the PET maximum standardized uptake value (SUVmax). Results:Restaging level and decrease in CA19-9 correlated with improved TRG (p = .02 for both) as did restaging SUVmax (p < .01), yet there was no TRG correlation with decrease in SUVmax (p = .10) or CT response (p = .30). The TRG groups had similar OS and PFS except the TRG 0 (complete response) group. Compared to partial response levels (TRG 1-3, median OS 33.9 months, median PFS 13.0 months), the six (7%) patients with TRG 0 had no deaths (p = .05) and only one progression (p = .03). A group of 10 (12%) TRG 1 patients with only residual isolated tumor cells had similar outcomes to the other TRG 1-3 patients. Conclusion:Pre-operative PET-CT and CA19-9 response correlate with histopathologic tumor regression. Patients with complete pathologic response have superior outcomes, suggesting a rationale for intensification and personalization of neoadjuvant therapy in BRPC and LAPC. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
13. Squamous Cell Carcinoma Following Photodynamic Therapy for Cutaneous Bowen's Disease in a Series of 105 Patients.
- Author
-
RATOUR-BIGOT, Carole, CHEMIDLING, Mireille, MONTLAHUC, Claire, ABIRACHED, Georges, MADJLESSI, Nika, BULLIER, Chantal, BATTISTELLA, Maxime, BAGOT, Martine, LEBBE, Céleste, and BASSET-SEGUIN, Nicole
- Subjects
CANCER treatment ,SQUAMOUS cell carcinoma ,BOWEN'S disease ,PHOTODYNAMIC therapy ,IMMUNOCOMPROMISED patients ,SKIN diseases ,THERAPEUTICS - Abstract
Photodynamic therapy (PDT) is an alternative to surgery for Bowen's disease. This monocentric retrospective study included 105 patients with Bowen's disease, treated with PDT between 2007 and 2013, who received a total of 151 different PDT fields. Comparison of immunocompromised and non-immunocompromised patients revealed that the former often had a previous history of squamous cell carcinoma (SCC; p = 0.004) and received more PDT fields (p = 0.007) than the latter. At least one SCC occurred post-PDT in 16 out of 105 patients in a PDT field. However, many of the patients were at risk of SCC and the possibility that the lesion did not have a mixed histology at baseline, but might simply be a transformation of non-PDT-responsive Bowen's disease, cannot be excluded. Although it is rare, patients should be closely monitored for SCC post-PDT. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Central nervous system involvement in T-cell lymphoma: A single center experience.
- Author
-
Gurion, Ronit, Mehta, Neha, Migliacci, Jocelyn C, Zelenetz, Andrew, Moskowitz, Alison, Lunning, Matthew, Moskowitz, Craig, Hamlin, Paul, and Horwitz, Steven
- Subjects
METHOTREXATE ,CANCER treatment ,EVALUATION of medical care ,CENTRAL nervous system tumors ,SPECIALTY hospitals ,DISEASE incidence ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,T-cell lymphoma ,PREVENTION ,PROGNOSIS ,TUMOR risk factors - Abstract
BackgroundWe characterized the incidence of central nervous system (CNS) involvement, risk factors and outcome in a large single institution dataset of peripheral T-cell lymphoma (PTCL). MethodsRetrospective review of the PTCL database at Memorial Sloan Kettering Cancer Center. We identified 231 patients with any subtype of PTCL between 1994–2011 with a minimum six months of follow-up or an event defined as relapse or death. ResultsHistologies included peripheral T-cell lymphoma–not otherwise specified (PTCL–NOS) (31.6%), angioimmunoblastic (16.9%), anaplastic large cell lymphoma (ALCL), ALK- (12.1%), ALCL, ALK + (6.1%), extranodal NK/T-cell lymphoma (7.4%), adult T-cell leukemia/lymphoma (ATLL) (7.4%), and transformed mycosis fungoides (8.7%). Seventeen patients had CNS disease (7%). Fifteen had CNS involvement with PTCL and two had diffuse large B-cell lymphoma and glioblastoma. Median time to CNS involvement was 3.44 months (0.16–103.1). CNS prophylaxis was given to 24 patients (primarily intrathecal methotrexate). Rates of CNS involvement were not different in patients who received prophylaxis. Univariate analysis identified stage III–IV, bone marrow involvement, >1 extranodal site and ATLL as risk factors for CNS disease. On multivariate analysis, >1 extranodal site and international prognostic index (IPI) ≥ 3 were predictive for CNS involvement. The median survival of patients with CNS involvement was 2.63 months (0.10–75). ConclusionsDespite high relapse rates, PTCL, except ATLL, carries a low risk of CNS involvement. Prognosis with CNS involvement is poor and risk factors include: >1 extra nodal site and IPI ≥3. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
15. Outcomes of Bleomycin-based electrochemotherapy in patients with repeated loco-regional recurrences of vulvar cancer.
- Author
-
Pellegrino, Antonio, Damiani, Gianluca Raffaello, Mangioni, Costantino, Strippoli, Davide, Loverro, Giuseppe, Cappello, Antonio, Turoli Scd, Daniela, Corso, Silvia, Tartagni, Massimo, and Pezzotta, Maria Grazia
- Subjects
CANCER relapse ,VULVAR tumors ,BLEOMYCIN ,CANCER chemotherapy ,ELECTROTHERAPEUTICS ,INTRAVENOUS therapy ,QUALITY of life ,QUESTIONNAIRES ,TUMOR classification ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,TUMOR treatment ,CANCER treatment - Abstract
ObjectiveTo evaluate the safety, local tumor efficacy and relief of symptoms of electrochemotherapy (ECT) treatment in patients affected by recurrence of vulvar cancer (VC), unsuitable for standard treatments. MethodsTen patients were recruited with histological diagnosis of recurrence of VC. Intravenous bleomycin was injected, after an accurate mapping of all lesions and ECT was performed. Response to therapy was evaluated and quality of life (QoL) was evaluated via questionnaires. ResultsDiagnosis stage of primary tumors, according to the FIGO system, was: four patients respectively at stage IB (40%), and at stage II (40%), one patient at stage IIIA (10%), one patient with Paget cancer (10%). Mean age was 76 years (SD ± 7) at time of enrollment. Eight patients (80%) were previously submitted to surgery and/or radio-chemotherapy. Mean treatment time was 20 (range 10–20) min. After a median follow-up of 12 (3–22) months, six patients (60%) were alive. ConclusionsObjective responses (ORs) with local control of the tumor were obtained in 80%. After a mean follow-up of 12 (3–22) months six patients (60%) were alive. The favorable outcome of this study, indicates that ECT is a reliable treatment option that may improve their functioning, thus enhancing the care provided in the palliative setting. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
16. Failure pattern and salvage treatment after radical treatment of head and neck cancer.
- Author
-
Pagh, Anja, Grau, Cai, and Overgaard, Jens
- Subjects
CANCER treatment ,CANCER relapse ,HYPOPHARYNX ,ACADEMIC medical centers ,GLOTTIS ,PATIENT aftercare ,HEAD tumors ,TREATMENT effectiveness ,NECK tumors ,SALVAGE therapy ,EARLY diagnosis ,DESCRIPTIVE statistics ,TUMOR treatment ,DIAGNOSIS ,TUMORS ,PROGNOSIS - Abstract
PurposeThe aim of the study was to test the hypothesis that head and neck cancer (HNC) patients benefit from specialized follow-up (FU), as this strategy ensures timely detection of relapses for successful salvage treatment. This was done by evaluation of the pattern of failure, the temporal distribution of recurrences, and the outcome of salvage treatment in a contemporary cohort of HNC patients. MethodsThe study evaluated a cohort of 2062 consecutive patients treated with curative intent at Aarhus University Hospital from 1 January 2000 to 31 December 2013. The database of DAHANCA contained recordings of recurrent disease in 567 patients with primary tumors of the larynx, pharynx, oral cavity, nasal cavity, paranasal sinuses and salivary glands. A review of medical records was performed in order to update and supplement the database. ResultsFailures of the 567 patients were primarily in T-site (65%) followed by N-site (36%) and M-site (22%). The vast majority of the first recurrences occurred within the first years after primary treatment; 62%, 82%, and 91% within the first, second and third year, respectively. Totally, 51% were amenable for salvage treatment, and 44% benefited from salvage in terms of a complete response. Permanent tumor control was observed in 128 patients (23%) after one or two salvage attempts. The highest salvage rate was recorded in patients with primary glottic carcinoma (41%) and the lowest among hypopharyngeal cancers (2%). Asymptomatic recurrence was recorded in 12% of all recurrences and this was found to be a positive prognostic factor for disease-specific survival, as they had significantly better outcome after salvage. ConclusionOur data support the usefulness of specialized FU in terms of early detection of recurrent disease. In particular patients with silent recurrences benefited from early detection, as they had a significantly lower risk ratio of death from primary HNC. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
17. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses.
- Author
-
Nkhali, Lamyaa, Thureau, Sébastien, Edet-Sanson, Agathe, Doyeux, Kaya, Benyoucef, Ahmed, Gardin, Isabelle, Michel, Pierre, Vera, Pierre, and Dubray, Bernard
- Subjects
CANCER treatment ,SQUAMOUS cell carcinoma ,CANCER chemotherapy ,COMBINED modality therapy ,COMPUTED tomography ,DEOXY sugars ,ESOPHAGEAL tumors ,LONGITUDINAL method ,RADIATION doses ,RADIOPHARMACEUTICALS ,STATISTICS ,POSITRON emission tomography ,DATA analysis ,DATA analysis software ,DESCRIPTIVE statistics - Abstract
Background. A planning study investigated whether reduced target volumes defined on FDG-PET/CT during radiotherapy allow total dose escalation without compromising normal tissue tolerance in patients with esophageal cancer. Material and methods. Ten patients with esophageal squamous cell carcinoma (SCC), candidate to curative-intent concomitant chemo-radiotherapy (CRT), had FDG-PET/CT performed in treatment position, before and during (Day 21) radiotherapy (RT). Four planning scenarios were investigated: 1) 50 Gy total dose with target volumes defined on pre-RT FDG-PET/CT; 2) 50 Gy with boost target volume defined on FDG-PET/CT during RT; 3) 66 Gy with target volumes from pre-RT FDG-PET/CT; and 4) 66 Gy with boost target volume from during-RT FDG-PET/CT. Results. The median metabolic target volume decreased from 12.9 cm
3 (minimum 3.7-maximum 44.8) to 5.0 cm3 (1.7-13.5) (p = 0.01) between pre- and during-RCT FDG-PET/CT. The median PTV66 was smaller on during-RT than on baseline FDG-PET/CT [108 cm3 (62.5-194) vs. 156 cm3 (68.8-251), p = 0.02]. When total dose was set to 50 Gy, planning on during-RT FDG-PET/CT was associated with a marginal reduction in normal tissues irradiation. When total dose was increased to 66 Gy, planning on during-RT PET yielded significantly lower doses to the spinal cord [Dmax = 44.1Gy (40.8-44.9) vs. 44.7Gy (41.5-45.0), p = 0.007] and reduced lung exposure [V20Gy = 23.2% (17.3-27) vs. 26.8% (19.7-30.2), p = 0.006]. Conclusion. This planning study suggests that adaptive RT based on target volume reduction assessed on FDG-PET/CT during treatment could facilitate dose escalation up to 66 Gy in patients with esophageal SCC. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
18. The role of behavioural modification and exercise in the management of cancer-related fatigue to reduce its impact during and after cancer treatment.
- Author
-
Minton, Ollie, Jo, Foster, and Jane, Maher
- Subjects
CANCER complications ,TUMOR treatment ,FATIGUE (Physiology) ,BEHAVIOR modification ,CANCER patients ,EXERCISE therapy ,HEALTH promotion ,MEDICAL personnel ,PATIENT compliance ,TIME ,COMORBIDITY ,OCCUPATIONAL roles ,CANCER treatment ,THERAPEUTICS - Abstract
Background. Fatigue is a symptom that can occur during treatment as an acute side effect but can also result in persistent fatigue as a long-term side effect or late effect. Materials and methods. We undertook a narrative review of the current literature and discuss the current evidence of assessment of fatigue and we specifically focus on the role of promoting behavioural change and focused rehabilitation to minimise these long-term effects and update the literature relating to this area from 2012 to date. Results. We suggest there are behavioural change models that can be scaled up to enable patients to manage long-term fatigue using exercise. However, from this updated review there are limitations to the current infrastructure and evidence base that will impact on the ability to do this. Conclusion. We continually need to raise awareness amongst health professionals to continue to suggest modifications to impact on fatigue at all stages of cancer treatment and into survivorship and late effects. These can range from simple brief interventions suggested in the clinic to full scale rehabilitation programmes if the correct infrastructure is available. Whichever approach is adopted we suggest exercise will be the mainstay of the treatment of fatigue in this group. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
19. Metastatic Melanoma -- A Review of Current and Future Treatment Options.
- Author
-
MAVERAKIS, Emanual, CORNELIUS, Lynn A., BOWEN, Glen M., PHAN, Tiffany, PATEL, Falin B., FITZMAURICE, Sarah, Young HE, BURRALL, Barbara, DUONG, Christopher, KLOXIN, April M., SULTANI, Hawa, WILKEN, Reason, MARTINEZ, Steve R., and PATEL, Forum
- Subjects
MELANOMA treatment ,MELANOMA immunotherapy ,CANCER treatment ,THERAPEUTIC use of monoclonal antibodies ,THERAPEUTIC use of immunoglobulins - Abstract
Despite advances in treatment and surveillance, melanoma continues to claim approximately 9,000 lives in the US annually (SEER 2013). The National Comprehensive Cancer Network currently recommends ipilumumab, vemurafenib, dabrafenib, and high-dose IL-2 as first line agents for Stage IV melanoma. Little data exists to guide management of cutaneous and subcutaneous metastases despite the fact that they are relatively common. Existing options include intralesional Bacillus Calmette-Guérin, isolated limb perfusion/infusion, interferon-α, topical imiquimod, cryotherapy, radiation therapy, interferon therapy, and intratumoral interleukin-2 injections. Newly emerging treatments include the anti-programmed cell death 1 receptor agents (nivolumab and pembrolizumab), anti-programmed death-ligand 1 agents, and oncolytic vaccines (talimogene laherparepevec). Available treatments for select sites include adoptive Tcell therapies and dendritic cell vaccines. In addition to reviewing the above agents and their mechanisms of action, this review will also focus on combination therapy as these strategies have shown promising results in clinical trials for metastatic melanoma treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. Characterization of patients receiving palliative chemo- and radiotherapy during end of life at a regional cancer center in Norway.
- Author
-
Anshushaug, Malin, Gynnild, Mari Aas, Kaasa, Stein, Kvikstad, Anne, and Grønberg, Bjørn H.
- Subjects
TUMOR classification ,CANCER chemotherapy ,CANCER patients ,CANCER treatment ,CHI-squared test ,MULTIVARIATE analysis ,PALLIATIVE treatment ,RADIOTHERAPY ,SURVIVAL analysis (Biometry) ,TERMINAL care ,LOGISTIC regression analysis ,SPECIALTY hospitals ,PROPORTIONAL hazards models ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator - Abstract
Background. Many cancer patients receive chemotherapy and radiotherapy their last 30 days [end of life (EOL)]. The benefit is questionable and side effects are common. The aim of this study was to investigate what characterized the patients who received chemo- and radiotherapy during EOL, knowledge that might be used to improve practice. Methods. Patients dead from cancer in 2005 and 2009 were analyzed. Data were collected from hospital medical records. When performance status (PS) was not stated, PS was estimated from other information in the records. A Glasgow Prognostic Score (GPS) of 0, 1 or 2 was assessed from blood values (CRP and albumin). A higher score is associated with a shorter prognosis. Results. In total 616 patients died in 2005; 599 in 2009. Among the 723 analyzed, median age was 71; 42% had metastases at diagnosis (synchronous metastases); 53% had PS 2 and 16% PS 3-4 at the start of last cancer therapy. GPS at the start of last cancer therapy was assessable in 70%; of these, 26% had GPS 1 and 35% GPS 2. Overall, 10% received chemotherapy and 8% radiotherapy during EOL. The proportions varied significantly between the different types of cancer. Multivariate analyses revealed that those at age < 70 years, GPS 2, no contact with our Palliative Care Unit and synchronous metastases received most chemotherapy the last 30 days. PS 3-4, GPS 2 and synchronous metastases were strongest associated with radiotherapy the last 30 days. Conclusion. Ten percent received chemotherapy and 8% radiotherapy the last 30 days of life. GPS 2 and synchronous metastases were most significantly associated with cancer therapy the last 30 days of life, indicating that in general, patients with the shortest survival time after diagnosis of cancer received more chemo- and radiotherapy during EOL than other patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
21. Squamous Cell Carcinoma of the Skin has More Than Doubled Over the Last Decade in the UK.
- Author
-
Goon, Peter K. C., Greenberg, David C., Igali, Laszlo, and Levell, Nick J.
- Subjects
CANCER treatment ,SQUAMOUS cell carcinoma ,CARCINOMA ,DISEASES in older people ,CAUCASIAN race ,SKIN cancer ,THERAPEUTICS - Abstract
The article presents a study which examined surgical procedures done in patients with squamous cell carcinoma (SCC) in East Norfolk and Waveney (ENW) in the Eastern Region of Great Britain between 2003 and 2012. The variables considered include skin SCC histology, pathological diagnostic, percentage of elderly people and percentage of white people. A discussion on the incidence of non-melanoma skin cancer (NMSC).
- Published
- 2016
- Full Text
- View/download PDF
22. Epidermal Cyst Formation and Hyperkeratosis in a Patient Treated with Vismodegib for Locally Advanced Basal Cell Carcinoma.
- Author
-
Reinders, Marie G. H. C., Brinkhuizen, Tjinta, Soetekouw, Patricia M. M. B., Kelleners-Smeets, Nicole W. J., Abdul Hamid, Myrurgia A., and Mosterd, Klara
- Subjects
BASAL cell carcinoma treatment ,SKIN cancer ,CANCER treatment ,VISMODEGIB - Abstract
The article describes the case of a 52-year-old man with epidermal cyst formation and hyperkeratosis due to vismodegib treatment for locally advanced basal cell carcinoma (BCC). Topics discussed include the five stages of Moh's micrographic surgery done on the patient to achieve clear margins and the result of the patient's histological examination which showed residual infiltrative BCC, accompanied by epidermal cyst formation and some hyperkeratosis.
- Published
- 2015
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.